Abbott has finished enrolling some 2,800 patients in three clinical trials evaluating its Absorb system, a dissolving, drug-eluting scaffold intended to treat patients with heart vessel blockage. The trials, being conducted in the U.S., Japan and China, are meant to back the company's regulatory approval applications for the device in the three countries.

Related Summaries